Henry Schein (HSIC) Earning Somewhat Positive News Coverage, Study Finds
Headlines about Henry Schein (NASDAQ:HSIC) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Henry Schein earned a news impact score of 0.21 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 47.0101475681832 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the headlines that may have impacted Accern’s rankings:
- Kimberly-Clark Corporation (KMB) Swings on Assorted News – Henry Schein, Inc. (HSIC) – Investing News Update (investingbizz.com)
- Keep Your Active Eyes on Henry Schein, Inc. (HSIC) – Wall Street Morning (wallstreetmorning.com)
- Henry Schein, Inc. (HSIC) to Post Q3 2018 Earnings of $1.14 Per Share, William Blair Forecasts (americanbankingnews.com)
- Wired News – Henry Schein Buys Controlling Stake in Brazil’s Veterinary Health Care Products Distributor ABASE (finance.yahoo.com)
- Henry Schein (HSIC) Acquires Majority Interest In ABASE – StreetInsider.com (streetinsider.com)
HSIC has been the topic of several research reports. Jefferies Group restated a “hold” rating and issued a $88.50 target price on shares of Henry Schein in a research note on Thursday, September 28th. Morgan Stanley lowered Henry Schein from an “equal weight” rating to an “underweight” rating and set a $88.00 target price on the stock. in a research note on Wednesday, December 6th. Evercore ISI initiated coverage on Henry Schein in a research note on Thursday, January 4th. They issued an “outperform” rating and a $81.00 target price on the stock. Zacks Investment Research lowered Henry Schein from a “hold” rating to a “sell” rating in a research note on Monday, November 13th. Finally, Robert W. Baird set a $95.00 target price on Henry Schein and gave the company a “buy” rating in a research note on Thursday, October 19th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $84.23.
Henry Schein (NASDAQ HSIC) traded up $1.54 during trading hours on Friday, hitting $74.84. The company had a trading volume of 1,045,500 shares, compared to its average volume of 1,700,000. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.86 and a current ratio of 1.55. Henry Schein has a 12 month low of $65.28 and a 12 month high of $93.50. The company has a market cap of $11,750.00, a price-to-earnings ratio of 21.57, a price-to-earnings-growth ratio of 1.89 and a beta of 0.99.
Henry Schein (NASDAQ:HSIC) last released its quarterly earnings data on Monday, November 6th. The company reported $0.87 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). Henry Schein had a net margin of 4.52% and a return on equity of 19.71%. The company had revenue of $3.16 billion for the quarter, compared to the consensus estimate of $3.05 billion. During the same quarter in the previous year, the firm posted $0.84 earnings per share. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. sell-side analysts predict that Henry Schein will post 3.6 EPS for the current fiscal year.
Henry Schein announced that its board has initiated a share repurchase plan on Monday, September 18th that authorizes the company to buyback $400.00 million in outstanding shares. This buyback authorization authorizes the company to repurchase up to 6.3% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board believes its stock is undervalued.
In related news, Director Barry J. Alperin sold 5,796 shares of the business’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $70.76, for a total transaction of $410,124.96. Following the sale, the director now directly owns 48,172 shares in the company, valued at approximately $3,408,650.72. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.19% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Henry Schein (HSIC) Earning Somewhat Positive News Coverage, Study Finds” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.watchlistnews.com/henry-schein-hsic-earning-somewhat-positive-news-coverage-study-finds/1804969.html.
Henry Schein Company Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.